Tumor necrosis factor receptor superfamily member 8 (CD30) (TNFRSF8)

Tumor necrosis factor receptor superfamily member 8 (TNFRSF8), commonly known as CD30, is a type I transmembrane glycoprotein that serves as a critical mediator of cell growth and survival signaling (UniProt P28908). The intracellular domain of CD30 is vital for its function, as it lacks intrinsic enzymatic activity and instead recruits TNF receptor-associated factors (TRAFs), such as TRAF1, TRAF2, and TRAF5, to initiate downstream signaling (PubMed: 11015445). These interactions primarily activate the NF-kappaB and mitogen-activated protein kinase (MAPK) pathways, which regulate the balance between cell proliferation and apoptosis (NCBI Gene: 943). While CD30 expression is normally restricted to a small subset of activated lymphocytes, it is highly and constitutively expressed in several malignancies, most notably Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL) (PubMed: 25224414). This differential expression makes CD30 an ideal therapeutic target, leading to the development of the antibody-drug conjugate brentuximab vedotin, which delivers a cytotoxic agent directly to CD30-positive cells (FDA). Beyond its role as a docking site for signaling proteins, the intracellular domain is also being explored for its potential in chimeric antigen receptor (CAR) T-cell designs to enhance T-cell persistence and activity (PubMed: 30333116).

Other names

CD30Ki-1 antigenD1S166ELymphocyte activation antigen CD30TNFRSF8

Antibody-drug conjugate (ADC) binding to the extracellular domain followed by receptor-mediated endocytosis and intracellular release of a cytotoxic payload (e.g., monomethyl auristatin E), leading to microtubule disruption and cell death.